Literature DB >> 8495277

Glucocorticoid effects on statural growth.

L V Avioli1.   

Abstract

Glucocorticoid use in children is not only associated with the side effects which are seen in adults, but also with severe adverse effects on statural growth. As little as 2.5-5.0 mg prednisolone/day can cause a retardation in statural growth. A direct relationship exists between the dose of glucocorticoid used and statural growth. The use of knemometry, a sensitive technique for measuring the growth of long bones in children has increased the accuracy of growth rate measurements. Many factors, such as disease process, sex, daily vs alternate day therapy, ethnic variations or whether the patient has been immobilized must be considered when evaluating the effects on stature of a particular glucocorticoid. Although alternate day therapy may benefit some patients (particularly those with juvenile chronic arthritis), not all patients respond beneficially to this type of regimen. New generations of glucocorticoids which may not be as detrimental to the growing child should now be considered.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8495277     DOI: 10.1093/rheumatology/32.suppl_2.27

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  8 in total

1.  The impact of corticosteroids on growth and bone health.

Authors:  T Mushtaq; S F Ahmed
Journal:  Arch Dis Child       Date:  2002-08       Impact factor: 3.791

2.  Presumed Pseudotumor Cerebri Syndrome After Withdrawal of Inhaled Glucocorticoids.

Authors:  Young Joon Kwon; Julian L Allen; Grant T Liu; Shana E McCormack
Journal:  Pediatrics       Date:  2016-05-17       Impact factor: 7.124

3.  Calcium and vitamin D for osteoprotection in children with new-onset nephrotic syndrome treated with steroids: a prospective, randomized, controlled, interventional study.

Authors:  Surabhi Choudhary; Indira Agarwal; Mandalam S Seshadri
Journal:  Pediatr Nephrol       Date:  2014-01-12       Impact factor: 3.714

4.  Dexamethasone stimulates expression of C-type Natriuretic Peptide in chondrocytes.

Authors:  Hanga Agoston; Laurie Baybayan; Frank Beier
Journal:  BMC Musculoskelet Disord       Date:  2006-11-20       Impact factor: 2.362

5.  VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.

Authors:  Christopher R Heier; Jesse M Damsker; Qing Yu; Blythe C Dillingham; Tony Huynh; Jack H Van der Meulen; Arpana Sali; Brittany K Miller; Aditi Phadke; Luana Scheffer; James Quinn; Kathleen Tatem; Sarah Jordan; Sherry Dadgar; Olga C Rodriguez; Chris Albanese; Michael Calhoun; Heather Gordish-Dressman; Jyoti K Jaiswal; Edward M Connor; John M McCall; Eric P Hoffman; Erica K M Reeves; Kanneboyina Nagaraju
Journal:  EMBO Mol Med       Date:  2013-09-09       Impact factor: 12.137

6.  Membrane-stabilizing copolymers confer marked protection to dystrophic skeletal muscle in vivo.

Authors:  Evelyne M Houang; Karen J Haman; Antonio Filareto; Rita C Perlingeiro; Frank S Bates; Dawn A Lowe; Joseph M Metzger
Journal:  Mol Ther Methods Clin Dev       Date:  2015-11-11       Impact factor: 6.698

Review 7.  Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors.

Authors:  Shouta Miyatake; Yuko Shimizu-Motohashi; Shin'ichi Takeda; Yoshitsugu Aoki
Journal:  Drug Des Devel Ther       Date:  2016-08-30       Impact factor: 4.162

8.  The Impact of Postnatal Systemic Steroids on the Growth of Preterm Infants: A Multicenter Cohort Study.

Authors:  Carlos Zozaya; Alejandro Avila-Alvarez; Fermín García-Muñoz Rodrigo; María L Couce; Luis Arruza; Cristina Fernandez-Perez; Abdón Castro; María Teresa Cuesta; Beatriz Vacas; Máximo Vento; Miguel Saenz de Pipaón
Journal:  Nutrients       Date:  2019-11-11       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.